Noradrenergic system in theneurobiology of depression;El sistema noradrenérgico en la neurobiología de la depresión the

Psiquiatria Biologica

Volumn 15, Issue 5, 2008, Pages 162-174

  Ortega, Jorge Emilio ^a,b   Meana, Luis Felipe Callado Y José Javier ^a  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Antidepressants; Noradrenergic system; 2 adrenoceptors

Indexed keywords

2 (2 METHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; CLORGYLINE; DESIPRAMINE; DULOXETINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; IPRONIAZID; PAROXETINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ZIMELDINE;

ANATOMY; CENTRAL NERVOUS SYSTEM; DEPRESSION; DRUG MECHANISM; HUMAN; LOCUS CERULEUS; MONOAMINERGIC SYSTEM; NEUROBIOLOGY; NEUROTRANSMISSION; NORADRENERGIC SYSTEM; PATHOPHYSIOLOGY; REVIEW; SEROTONINERGIC SYSTEM; THERAPY EFFECT;

EID: 60849101854     PISSN: 11345934     EISSN: 15788962     Source Type: Journal    
DOI: 10.1016/s1134-5934(08)76487-x     Document Type: Review

References (120)

1. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci. 2006;7:137-51.
2. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965;122:509-22.
3. Van Praag HM. Depression, suicide and serotonin metabolism in the brain. En: Post RM, Ballenger JC, editores. Neu-robiology of mood disorders. Baltimore: Williams & Wil-kins; 1984.
4. Ballesteros J, Callado LF, Gutierrez M. An independent me-ta-analysis using summary data for clinical response, remission, and discontinuation for any reason from the 6 pivotal phase III randomized clinical trials of duloxetine in major depressive disorder. J Clin Psychopharmacol. 2007;27:219-21.
5. Heninger GR, Delgado PL, Charney DS. The revised mono-amine theory of depression: a modulatory role for monoami-nes, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry. 1996;29:2-11.
6. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry. 1990;47:411-8.
7. Delgado PL, Miller HL, Salomon RM, Licinio J, Krystal JH, Moreno FA, et al. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antide-pressant action. Biol Psychiatry. 1999;46:212-20.
8. Miller HL, Delgado PL, Salomon RM, Berman R, Krystal JH, Heninger GR, et al. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry. 1996;53:117-28.
9. Delgado PL, Miller HL, Salomon RM, Licinio J, Heninger GR, Gelenberg AJ, et al. Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychophar-macol Bull. 1993;29:389-96.
10. Young SN, Smith SE, Pihl RO, Ervin FR. Tryptophan depletion causes a rapid lowering of mood in normal males. Psy-chopharmacology (Berl). 1985;87:173-7.
11. Smith SE, Pihl RO, Young SN, Ervin FR. A test of possible cognitive and environmental influences on the mood lowering effect of tryptophan depletion in normal males. Psy-chopharmacology (Berl). 1987;91:451-7.
12. Smith KA, Fairburn CG, Cowen PJ. Relapse of depression after rapid depletion of tryptophan. Lancet. 1997;349:915-9.
13. Moreno FA, Gelenberg AJ, Heninger GR, Potter RL, McKnight KM, Allen J, et al. Tryptophan depletion and depressive vulnerability. Biol Psychiatry. 1999;46:498-505.
14. Benkelfat C, Ellenbogen MA, Dean P, Palmour RM, Young SN. Mood-lowering effect of tryptophan depletion. Enhanced susceptibility in young men at genetic risk for major affective disorders. Arch Gen Psychiatry. 1994;51:687-97.
15. Blier P, De Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci. 1994; 15:220-6.
16. Artigas F, Romero L, De Montigny C, Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci. 1996; 19:378-83.
17. Swanson LW. The locus coeruleus: a cytoarchitectonic, Gol-gi and immunohistochemical study in the albino rat. Brain Res. 1976;110:39-56.
18. Grzanna R, Molliver ME. The locus coeruleus in the rat: an immunohistochemical delineation. Neuroscience. 1980;5:21-40.
19. Moore RY, Bloom FE. Central catecholamine neuron systems: anatomy and physiology of the norepinephrine and epinephrine systems. Annu Rev Neurosci. 1979;2:113-68.
20. Levitt P, Moore RY. Noradrenaline neuron innervation of the neocortex in the rat. Brain Res. 1978;139:219-31.
21. Aston-Jones G, Shipley MT, Chouvet G, Ennis M, Van Bockstaele E, Pieribone V, et al. Afferent regulation of locus coeruleus neurons: anatomy, physiology and pharmacology. Prog Brain Res. 1991;88:47-75.
22. Luppi PH, Charlety PJ, Fort P, Akaoka H, Chouvet G, Jou-vet M. Anatomical and electrophysiological evidence for a glycinergic inhibitory innervation of the rat locus coeruleus. Neurosci Lett. 1991;128:33-6.
23. Cedarbaum JM, Aghajanian GK. Afferent projections to the rat locus coeruleus as determined by a retrograde tracing technique. J Comp Neurol. 1978;178:1-16.
24. Olpe HR, Steinmann M. Responses of locus coeruleus neurons to neuropeptides. Prog Brain Res. 1991;88:241-8.
25. Kiyashchenko LI, Mileykovskiy BY, Maidment N, Lam HA, Wu MF, John J, et al. Release of hypocretin (orexin) during waking and sleep states. J Neurosci. 2002;22:5282-6.
26. Aston-Jones G, Bloom FE. Activity of norepinephrine-con-taining locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking cycle. J Neurosci. 1981;1:876-86.
27. Foote SL, Berridge CW, Adams LM, Pineda JA. Electrophy-siological evidence for the involvement of the locus coeru-leus in alerting, orienting, and attending. Prog Brain Res. 1991;88:521-32.
28. Jones SL, Gebhart GF. Quantitative characterization of ceru-leospinal inhibition of nociceptive transmission in the rat. J Neurophysiol. 1986;56:1397-410.
29. Sagen J, Proudfit HK. Effect of intrathecally administered noradrenergic antagonists on nociception in the rat. Brain Res. 1984;310:295-301.
30. Sagen J, Winker MA, Proudfit HK. Hypoalgesia induced by the local injection of phentolamine in the nucleus raphe magnus: blockade by depletion of spinal cord monoamines. Pain. 1983;16:253-63.
31. Sullivan RM, Wilson DA, Lemon C, Gerhardt GA. Bilateral 6-OHDA lesions of the locus coeruleus impair associative olfactory learning in newborn rats. Brain Res. 1994;643:306-9.
32. Singewald N, Kaehler ST, Philippu A. Noradrenaline release in the locus coeruleus of conscious rats is triggered by drugs, stress and blood pressure changes. Neuroreport. 1999;10:1583-7.
33. Curtis AL, Drolet G, Valentino RJ. Hemodynamic stress activates locus coeruleus neurons of unanesthetized rats. Brain Res Bull. 1993;31:737-44.
34. Stanford SC. Central noradrenergic neurones and stress. Pharmacol Ther. 1995;68:297-42.
35. Bremner JD, Krystal JH, Southwick SM, Charney DS. Nora-drenergic mechanisms in stress and anxiety: I. Preclinical studies. Synapse. 1996;23:28-38.
36. Maldonado R, Koob GF. Destruction of the locus coeruleus decreases physical signs of opiate withdrawal. Brain Res. 1993;605:128-38.
37. Kogan JH, Nestler EJ, Aghajanian GK. Elevated basal firing rates and enhanced responses to 8-Br-cAMP in locus coeru-leus neurons in brain slices from opiate-dependent rats. Eur J Pharmacol. 1992;211:47-53.
38. Reches A, Meiner Z. The locus coeruleus and dopaminergic function in rat brain: implications to parkinsonism. Brain Res Bull. 1992;28:663-6.
39. Chan-Palay V. Alterations in the locus coeruleus in dementias of Alzheimer's and Parkinson's disease. Prog Brain Res. 1991;88:625-30.
40. Wolfe BB, Harden TK, Sporn JR, Molinoff PB. Presynaptic modulation of beta adrenergic receptors in rat cerebral cortex after treatment with antidepressants. J Pharmacol Exp Ther. 1978;207:446-57.
41. Danysz W, Kostowski W, Hauptmann M. Evidence for the locus coeruleus involvement in desipramine action in animal models of depression. Pol J Pharmacol Pharm. 1985;37:855-64.
42. Cortes R, Soriano E, Pazos A, Probst A, Palacios JM. Auto-radiography of antidepressant binding sites in the human brain: localization using [3H]imipramine and [3H]paroxeti-ne. Neuroscience. 1988;27:473-96.
43. Bruss M, Porzgen P, Bryan-Lluka LJ, Bonisch H. The rat norepinephrine transporter: molecular cloning from PC12 cells and functional expression. Brain Res Mol Brain Res. 1997;52:257-62.
44. Holton KL, Loder MK, Melikian HE. Nonclassical, distinct endocytic signals dictate constitutive and PKC-regulated neurotransmitter transporter internalization. Nat Neurosci. 2005;8:881-8.
45. Porzgen P, Bonisch H, Bruss M. Molecular cloning and organization of the coding region of the human norepinephrine transporter gene. Biochem Biophys Res Commun. 1995;215:1145-50.
46. Hahn MK, Mazei-Robison MS, Blakely RD. Single nucleoti-de polymorphisms in the human norepinephrine transporter gene affect expression, trafficking, antidepressant interaction, and protein kinase C regulation. Mol Pharmacol. 2005;68:457-66.
47. Inoue K, Itoh K, Yoshida K, Shimizu T, Suzuki T. Positive association between T-182C polymorphism in the norepinephrine transporter gene and susceptibility to major depressive disorder in a Japanese population. Neuropsychobiology. 2004;50:301-4.
48. Yoshida K, Takahashi H, Higuchi H, Kamata M, Ito K, Sato K, et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry. 2004;161:1575-80.
49. Tejani-Butt SM. [3H]nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by ho-mogenate binding. J Pharmacol Exp Ther. 1992;260:427-36.
50. Benmansour S, Altamirano AV, Jones DJ, Sanchez TA, Gould GG, Pardon MC, et al. Regulation of the norepineph-rine transporter by chronic administration of antidepressants. Biol Psychiatry. 2004;55:313-6.
51. Gould GG, Pardon MC, Morilak DA, Frazer A. Regulatory effects of reboxetine treatment alone, or following paroxeti-ne treatment, on brain noradrenergic and serotonergic systems. Neuropsychopharmacology. 2003;28:1633-41.
52. Szot P, Ashliegh EA, Kohen R, Petrie E, Dorsa DM, Veith R. Norepinephrine transporter mRNA is elevated in the locus coeruleus following short- and long-term desipramine treatment. Brain Res. 1993;618:308-12.
53. Zhu MY, Kim CH, Hwang DY, Baldessarini RJ, Kim KS. Effects of desipramine treatment on norepinephrine transporter gene expression in the cultured SK-N-BE(2)M17 cells and rat brain tissue. J Neurochem. 2002;82:146-53.
54. Lee CM, Javitch JA, Snyder SH. Recognition sites for nore-pinephrine uptake: regulation by neurotransmitter. Science. 1983;220:626-9.
55. Zhu MY, Ordway GA. Down-regulation of norepinephrine transporters on PC12 cells by transporter inhibitors. J Neurochem. 1997;68:134-41.
56. Mandela P, Ordway GA. The norepinephrine transporter and its regulation. J Neurochem. 2006;97:310-33.
57. Small KM, Forbes SL, Brown KM, Liggett SB. An asn to lys polymorphism in the third intracellular loop of the human alpha 2A-adrenergic receptor imparts enhanced agonist-promoted Gi coupling. J Biol Chem. 2000;275:38518-23.
58. Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefko-witz RJ, Minneman KP, et al. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev. 1994;46:121-36.
59. Lipscombe D, Kongsamut S, Tsien RW. Alpha-adrenergic inhibition of sympathetic neurotransmitter release mediated by modulation of N-type calcium-channel gating. Nature. 1989;340:639-42.
60. North RA, Yoshimura M. The actions of noradrenaline on neurones of the rat substantia gelatinosa in vitro. J Physiol. 1984;349:43-55.
61. Sweatt JD, Johnson SL, Cragoe EJ, Limbird LE. Inhibitors of Na+/H+ exchange block stimulus-provoked arachidonic acid release in human platelets. Selective effects on platelet activation by epinephrine, ADP, and lower concentrations of thrombin. J Biol Chem. 1985;260:12910-9.
62. Pazos A, Gonzalez AM, Pascual J, Meana JJ, Barturen F, Garcia-Sevilla JA. Alpha 2-adrenoceptors in human fore-brain: autoradiographic visualization and biochemical parameters using the agonist [3H]UK-14304. Brain Res. 1988; 475:361-5.
63. Nicholas AP, Pieribone V, Hokfelt T. Distributions of mR-NAs for alpha-2 adrenergic receptor subtypes in rat brain: an in situ hybridization study. J Comp Neurol. 1993;328:575-94.
64. Scheinin M, Lomasney JW, Hayden-Hixson DM, Schambra UB, Caron MG, Lefkowitz RJ, et al. Distribution of alpha 2-adrenergic receptor subtype gene expression in rat brain. Brain Res Mol Brain Res. 1994;21:133-49.
65. Tavares A, Handy DE, Bogdanova NN, Rosene DL, Gavras H. Localization of alpha 2A- and alpha 2B-adrenergic receptor subtypes in brain. Hypertension. 1996;27:449-55.
66. Sastre M, Garcia-Sevilla JA. Alpha 2-adrenoceptor subtypes identified by [3H]RX821002 binding in the human brain: the agonist guanoxabenz does not discriminate different forms of the predominant alpha 2A subtype. J Neurochem. 1994;63:1077-85.
67. Aoki C, Go CG, Venkatesan C, Kurose H. Perikaryal and sy-naptic localization of alpha 2A-adrenergic receptor-like im-munoreactivity. Brain Res. 1994;650:181-204.
68. Lee A, Rosin DL, Van Bockstaele EJ. alpha2A-adrenergic receptors in the rat nucleus locus coeruleus: subcellular localization in catecholaminergic dendrites, astrocytes, and presynaptic axon terminals. Brain Res. 1998;795:157-69.
69. Starke K. Presynaptic alpha-autoreceptors. Rev Physiol Bio-chem Pharmacol. 1987;107:73-146.
70. Dalley JW, Stanford SC. Contrasting effects of the imida-zol(in)e alpha 2-adrenoceptor agonists, medetomidine, cloni-dine and UK 14,304 on extraneuronal levels of noradrenaline in the rat frontal cortex: evaluation using in vivo microdialy-sis and synaptosomal uptake studies. Br J Pharmacol. 1995;114:1717-23.
71. Dennis T, L'Heureux R, Carter C, Scatton B. Presynaptic alpha-2 adrenoceptors play a major role in the effects of ida-zoxan on cortical noradrenaline release (as measured by in vivo dialysis) in the rat. J Pharmacol Exp Ther. 1987;241:642-9.
72. Cedarbaum JM, Aghajanian GK. Noradrenergic neurons of the locus coeruleus: inhibition by epinephrine and activation by the alpha-antagonist piperoxane. Brain Res. 1976;112:413-9.
73. Florin-Lechner SM, Druhan JP, Aston-Jones G, Valentino RJ. Enhanced norepinephrine release in prefrontal cortex with burst stimulation of the locus coeruleus. Brain Res. 1996;742:89-97.
74. Svensson TH, Bunney BS, Aghajanian GK. Inhibition of both noradrenergic and serotonergic neurons in brain by the alpha-adrenergic agonist clonidine. Brain Res. 1975;92:291-306.
75. Mateo Y, Meana JJ. Determination of the somatodendritic alpha2-adrenoceptor subtype located in rat locus coeruleus that modulates cortical noradrenaline release in vivo. Eur J Pharmacol. 1999;379:53-7.
76. Fernandez-Pastor B, Meana JJ. In vivo tonic modulation of the noradrenaline release in the rat cortex by locus coeruleus somatodendritic alpha(2)-adrenoceptors. Eur J Pharmacol. 2002;442:225-9.
77. Freedman JE, Aghajanian GK. Idazoxan (RX 781094) selectively antagonizes alpha 2-adrenoceptors on rat central neurons. Eur J Pharmacol. 1984;105:265-72.
78. Kawahara Y, Kawahara H, Westerink BH. Tonic regulation of the activity of noradrenergic neurons in the locus coeru-leus of the conscious rat studied by dual-probe microdialy-sis. Brain Res. 1999;823:42-8.
79. Pudovkina OL, Westerink BH. Functional role of alpha1-adrenoceptors in the locus coeruleus: a microdialysis study. Brain Res. 2005;1061:50-6.
80. Callado LF, Stamford JA. Alpha2A- but not alpha2B/C-adre-noceptors modulate noradrenaline release in rat locus coeru-leus: voltammetric data. Eur J Pharmacol. 1999;366:35-9.
81. Fernandez-Pastor B, Mateo Y, Gomez-Urquijo S, Javier Me-ana J. Characterization of noradrenaline release in the locus coeruleus of freely moving awake rats by in vivo micro-dialysis. Psychopharmacology (Berl). 2005;180:570-9.
82. Shimizu N, Katoh Y, Hida T, Satoh K. The fine structural organization of the locus coeruleus in the rat with reference to noradrenaline contents. Exp Brain Res. 1979;37:139-48.
83. Esteban S, Llado J, Garcia-Sevilla JA. Alpha 2-autoreceptors and alpha 2-heteroreceptors modulating tyrosine and tryp-tophan hydroxylase activity in the rat brain in vivo: an investigation into the alpha 2-adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 1996;353:391-9.
84. Bucheler MM, Hadamek K, Hein L. Two alpha(2)-adrener-gic receptor subtypes, alpha(2A) and alpha(2C), inhibit transmitter release in the brain of gene-targeted mice. Neu-roscience. 2002;109:819-26.
85. Trendelenburg AU, Klebroff W, Hein L, Starke K. A study of presynaptic alpha2-autoreceptors in alpha2A/D-, alpha2B-and alpha2C-adrenoceptor-deficient mice. Naunyn Schmie-debergs Arch Pharmacol. 2001;364:117-30.
86. Ihalainen JA, Tanila H. In vivo regulation of dopamine and noradrenaline release by alpha2A-adrenoceptors in the mouse prefrontal cortex. Eur J Neurosci. 2002;15:1789-94.
87. Gothert M, Huth H, Schlicker E. Characterization of the receptor subtype involved in alpha-adrenoceptor-mediated mo dulation of serotonin release from rat brain cortex slices. Naunyn Schmiedebergs Arch Pharmacol. 1981;317:199-203.
88. Feuerstein TJ, Mutschler A, Lupp A, Van Velthoven V, Sch-licker E, Gothert M. Endogenous noradrenaline activates alpha 2-adrenoceptors on serotonergic nerve endings in human and rat neocortex. J Neurochem. 1993;61:474-80.
89. Beani L, Bianchi C, Giacomelli A, Tamberi F. Noradrenali-ne inhibition of acetylcholine release from guinea-pig brain. Eur J Pharmacol. 1978;48:179-93.
90. Anden N, Grabowska M. Pharmacological evidence for a stimulation of dopamine neurons by noradrenaline neurons in the brain. Eur J Pharmacol. 1976;39:275-82.
91. Dickinson SL, Gadie B, Tulloch IF. Alpha 1- and alpha 2-adrenoreceptor antagonists differentially influence locomo-tor and stereotyped behaviour induced by d-amphetamine and apomorphine in the rat. Psychopharmacology (Berl). 1988;96:521-7.
92. Plotsky PM, Cunningham ET Jr, Widmaier EP. Catechola-minergic modulation of corticotropin-releasing factor and adrenocorticotropin secretion. Endocr Rev. 1989;10:437-58.
93. Danzebrink RM, Gebhart GF. Antinociceptive effects of in-trathecal adrenoceptor agonists in a rat model of visceral no-ciception. J Pharmacol Exp Ther. 1990;253:698-705.
94. Vincent PA, Thornton JE, Peterson CS, Feder HH. Different roles of alpha-noradrenergic receptor subtypes in regulating lordosis. Pharmacol Biochem Behav. 1989;34:89-93.
95. Arnsten AF, Cai JX, Goldman-Rakic PS. The alpha-2 adre-nergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. J Neurosci. 1988;8:4287-98.
96. Menargues A, Obach R, Garcia-Sevilla JA. Modulation by antidepressant drugs of CNS postsynaptic alpha 2-adreno-ceptors mediating mydriasis in the rat. Naunyn Schmiede-bergs Arch Pharmacol. 1990;341:101-7.
97. Timmermans PB, Schoop AM, Kwa HY, Van Zwieten PA. Characterization of alpha-adrenoceptors participating in the central hypotensive and sedative effects of clonidine using yohimbine, rauwolscine and corynanthine. Eur J Pharmacol. 1981;70:7-15.
98. Bill DJ, Hughes IE, Stephens RJ. The effects of acute and chronic desipramine on the thermogenic and hypoactivity responses to alpha 2-agonists in reserpinized and normal mice. Br J Pharmacol. 1989;96:144-52.
99. Mavroidis ML, Kanter DR, Greenblum DN, Garver DL. Adrenergic-receptor desensitization and course of clinical improvement with desipramine treatment. Psychopharmaco-logy (Berl). 1984;83:295-6.
100. Garcia-Sevilla JA. The platelet alpha 2-adrenoceptor as a potential biological marker in depression. Br J Psychiatry Suppl. 1989;(4):67-72.
101. Giralt MT, Garcia-Sevilla JA. Acute and long-term regulation of brain alpha 2-adrenoceptors after manipulation of no-radrenergic transmission in the rat. Eur J Pharmacol. 1989;164:455-66.
102. Mateo Y, Fernandez-Pastor B, Meana JJ. Acute and chronic effects of desipramine and clorgyline on alpha(2)-adrenocep-tors regulating noradrenergic transmission in the rat brain: a dual-probe microdialysis study. Br J Pharmacol. 2001;133:1362-70.
103. Barturen F, Garcia-Sevilla JA. Long term treatment with de-sipramine increases the turnover of alpha 2-adrenoceptors in the rat brain. Mol Pharmacol. 1992;42:846-55.
104. Garcia-Sevilla JA, Guimon J, Garcia-Vallejo P, Fuster MJ. Biochemical and functional evidence of supersensitive platelet alpha 2-adrenoceptors in major affective disorder. Effect of long-term lithium carbonate treatment. Arch Gen Psychiatry. 1986;43:51-7.
105. Meana JJ, Garcia-Sevilla JA. Increased alpha 2-adrenoceptor density in the frontal cortex of depressed suicide victims. J Neural Transm. 1987;70:377-81.
106. Callado LF, Meana JJ, Grijalba B, Pazos A, Sastre M, Gar-cia-Sevilla JA. Selective increase of alpha2A-adrenoceptor agonist binding sites in brains of depressed suicide victims. J Neurochem. 1998;70:1114-23.
107. Gonzalez-Maeso J, Rodriguez-Puertas R, Meana JJ, Garcia-Sevilla JA, Guimon J. Neurotransmitter receptor-mediated activation of G-proteins in brains of suicide victims with mood disorders: selective supersensitivity of alpha(2A)-adrenoceptors. Mol Psychiatry. 2002;7:755-67.
108. Nomura S, Duman RS, Enna SJ. In vivo or in vitro exposure to imipramine reduces alpha 2-adrenoceptor-mediated inhibition of cyclic AMP production in rat brain cerebral cortical slices. Brain Res. 1987;410:195-8.
109. Linner L, Arborelius L, Nomikos GG, Bertilsson L, Svens-son TH. Locus coeruleus neuronal activity and noradrenaline availability in the frontal cortex of rats chronically treated with imipramine: effect of alpha 2-adrenoceptor blockade. Biol Psychiatry. 1999;46:766-74.
110. Esteban S, Llado J, Sastre-Coll A, Garcia-Sevilla JA. Activation and desensitization by cyclic antidepressant drugs of alpha2-autoreceptors, alpha2-heteroreceptors and 5-HT1A-autoreceptors regulating monamine synthesis in the rat brain in vivo. Naunyn Schmiedebergs Arch Pharmacol. 1999;360:135-43.
111. Invernizzi RW, Parini S, Sacchetti G, Fracasso C, Caccia S, Annoni K, et al. Chronic treatment with reboxetine by osmotic pumps facilitates its effect on extracellular noradrenaline and may desensitize alpha(2)-adrenoceptors in the prefrontal cortex. Br J Pharmacol. 2001;132:183-8.
112. Sacchetti G, Bernini M, Gobbi M, Parini S, Pirona L, Mennini T, et al. Chronic treatment with desipramine facilitates its effect on extracellular noradrenaline in the rat hippocampus: studies on the role of presynaptic alpha2-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol. 2001;363:66-72.
113. Parini S, Renoldi G, Battaglia A, Invernizzi RW. Chronic re-boxetine desensitizes terminal but not somatodendritic alp-ha2-adrenoceptors controlling noradrenaline release in the rat dorsal hippocampus. Neuropsychopharmacology. 2005;30:1048-55.
114. Millan MJ, Gobert A, Girardon S, Dekeyne A. Citalopram elicits a discriminative stimulus in rats at a dose selectively increasing extracellular levels of serotonin vs. dopamine and noradrenaline. Eur J Pharmacol. 1999;364:147-50.
115. Bymaster FP, Zhang W, Carter PA, Shaw J, Chernet E, Phe-bus L, et al. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl). 2002;160:353-61.
116. Thomas DN, Nutt DJ, Holman RB. Sertraline, a selective serotonin reuptake inhibitor modulates extracellular noradrena-line in the rat frontal cortex. J Psychopharmacol. 1998;12:366-70.
117. Scuvee-Moreau JJ, Svensson TH. Sensitivity in vivo of central alpha 2- and opiate receptors after chronic treatment with various antidepressants. J Neural Transm. 1982;54:51-63.
118. Grandoso L, Torrecilla M, Pineda J, Ugedo L. alpha(2)-Adrenoceptor involvement in the in vitro inhibitory effect of citalopram on a subpopulation of rat locus coeruleus neurons. Eur J Pharmacol. 2005;517:51-8.
119. Ballesteros J, Callado LF. Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials. J Affect Disord. 2004;79:137-47.
120. Nutt DJ. Efficacy of mirtazapine in clinically relevant subgroups of depressed patients. Depress Anxiety. 1998;7 Suppl 1:7-10.